Heart failure with preserved ejection fraction: Mechanisms, clinical features, and therapies

Research output: Contribution to journalArticle

Abstract

The clinical syndrome comprising heart failure (HF) symptoms but with a left ventricular ejection fraction (EF) that is not diminished, eg, HF with preserved EF, is increasingly the predominant form of HF in the developed world, and soon to reach epidemic proportions. It remains among the most challenging of clinical syndromes for the practicing clinician and scientist alike, with a multitude of proposed mechanisms involving the heart and other organs and complex interplay with common comorbidities. Importantly, its morbidity and mortality are on par with HF with reduced EF, and as the list of failed treatments continues to grow, HF with preserved EF clearly represents a major unmet medical need. The field is greatly in need of a more unified approach to its definition and view of the syndrome that engages integrative and reserve pathophysiology beyond that related to the heart alone. We need to reflect on prior treatment failures and the message this is providing, and redirect our approaches likely with a paradigm shift in how the disease is viewed. Success will require interactions between clinicians, translational researchers, and basic physiologists. Here, we review recent translational and clinical research into HF with preserved EF and give perspectives on its evolving demographics and epidemiology, the role of multiorgan deficiencies, potential mechanisms that involve the heart and other organs, clinical trials, and future directions.

Original languageEnglish (US)
Pages (from-to)79-96
Number of pages18
JournalCirculation Research
Volume115
Issue number1
DOIs
StatePublished - Jun 20 2014

Fingerprint

Heart Failure
Therapeutics
Translational Medical Research
Treatment Failure
Stroke Volume
Comorbidity
Epidemiology
Research Personnel
Demography
Clinical Trials
Morbidity
Mortality

Keywords

  • diastole
  • heart failure
  • hypertension
  • hypertrophy
  • therapy

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Heart failure with preserved ejection fraction : Mechanisms, clinical features, and therapies. / Sharma, Kavita; Kass, David A.

In: Circulation Research, Vol. 115, No. 1, 20.06.2014, p. 79-96.

Research output: Contribution to journalArticle

@article{f029a1c179ae4021a26c441fe3411e61,
title = "Heart failure with preserved ejection fraction: Mechanisms, clinical features, and therapies",
abstract = "The clinical syndrome comprising heart failure (HF) symptoms but with a left ventricular ejection fraction (EF) that is not diminished, eg, HF with preserved EF, is increasingly the predominant form of HF in the developed world, and soon to reach epidemic proportions. It remains among the most challenging of clinical syndromes for the practicing clinician and scientist alike, with a multitude of proposed mechanisms involving the heart and other organs and complex interplay with common comorbidities. Importantly, its morbidity and mortality are on par with HF with reduced EF, and as the list of failed treatments continues to grow, HF with preserved EF clearly represents a major unmet medical need. The field is greatly in need of a more unified approach to its definition and view of the syndrome that engages integrative and reserve pathophysiology beyond that related to the heart alone. We need to reflect on prior treatment failures and the message this is providing, and redirect our approaches likely with a paradigm shift in how the disease is viewed. Success will require interactions between clinicians, translational researchers, and basic physiologists. Here, we review recent translational and clinical research into HF with preserved EF and give perspectives on its evolving demographics and epidemiology, the role of multiorgan deficiencies, potential mechanisms that involve the heart and other organs, clinical trials, and future directions.",
keywords = "diastole, heart failure, hypertension, hypertrophy, therapy",
author = "Kavita Sharma and Kass, {David A}",
year = "2014",
month = "6",
day = "20",
doi = "10.1161/CIRCRESAHA.115.302922",
language = "English (US)",
volume = "115",
pages = "79--96",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Heart failure with preserved ejection fraction

T2 - Mechanisms, clinical features, and therapies

AU - Sharma, Kavita

AU - Kass, David A

PY - 2014/6/20

Y1 - 2014/6/20

N2 - The clinical syndrome comprising heart failure (HF) symptoms but with a left ventricular ejection fraction (EF) that is not diminished, eg, HF with preserved EF, is increasingly the predominant form of HF in the developed world, and soon to reach epidemic proportions. It remains among the most challenging of clinical syndromes for the practicing clinician and scientist alike, with a multitude of proposed mechanisms involving the heart and other organs and complex interplay with common comorbidities. Importantly, its morbidity and mortality are on par with HF with reduced EF, and as the list of failed treatments continues to grow, HF with preserved EF clearly represents a major unmet medical need. The field is greatly in need of a more unified approach to its definition and view of the syndrome that engages integrative and reserve pathophysiology beyond that related to the heart alone. We need to reflect on prior treatment failures and the message this is providing, and redirect our approaches likely with a paradigm shift in how the disease is viewed. Success will require interactions between clinicians, translational researchers, and basic physiologists. Here, we review recent translational and clinical research into HF with preserved EF and give perspectives on its evolving demographics and epidemiology, the role of multiorgan deficiencies, potential mechanisms that involve the heart and other organs, clinical trials, and future directions.

AB - The clinical syndrome comprising heart failure (HF) symptoms but with a left ventricular ejection fraction (EF) that is not diminished, eg, HF with preserved EF, is increasingly the predominant form of HF in the developed world, and soon to reach epidemic proportions. It remains among the most challenging of clinical syndromes for the practicing clinician and scientist alike, with a multitude of proposed mechanisms involving the heart and other organs and complex interplay with common comorbidities. Importantly, its morbidity and mortality are on par with HF with reduced EF, and as the list of failed treatments continues to grow, HF with preserved EF clearly represents a major unmet medical need. The field is greatly in need of a more unified approach to its definition and view of the syndrome that engages integrative and reserve pathophysiology beyond that related to the heart alone. We need to reflect on prior treatment failures and the message this is providing, and redirect our approaches likely with a paradigm shift in how the disease is viewed. Success will require interactions between clinicians, translational researchers, and basic physiologists. Here, we review recent translational and clinical research into HF with preserved EF and give perspectives on its evolving demographics and epidemiology, the role of multiorgan deficiencies, potential mechanisms that involve the heart and other organs, clinical trials, and future directions.

KW - diastole

KW - heart failure

KW - hypertension

KW - hypertrophy

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84902975038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902975038&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.115.302922

DO - 10.1161/CIRCRESAHA.115.302922

M3 - Article

C2 - 24951759

AN - SCOPUS:84902975038

VL - 115

SP - 79

EP - 96

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 1

ER -